Cargando…
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tr...
Autores principales: | Xiong, Luying, Wang, Xueting, Wang, Yuan, Yu, Wei, Zhou, Yanzi, Chi, Xiaohui, Xiao, Tingting, Xiao, Yonghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788277/ https://www.ncbi.nlm.nih.gov/pubmed/35891616 http://dx.doi.org/10.1002/wsbm.1571 |
Ejemplares similares
-
In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021) -
Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022) -
Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)